Prevalence of non-alcoholic fatty liver disease in type-2 diabetes mellitus patients

Authors

  • Hardik Patel Department of Medicine, Geetanjali Medical College and Hospital, Manwakhera NH-8 Bypass, Near Eklingpura Chouraha, Udaipur, Rajasthan, India
  • Yadav Narain Verma Department of Medicine, Geetanjali Medical College and Hospital, Manwakhera NH-8 Bypass, Near Eklingpura Chouraha, Udaipur, Rajasthan, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20181290

Keywords:

Hyperglycemia, Metabolic Syndrome, Non-alcoholic fatty liver disease, Type-2 diabetes mellitus

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a common chronic condition of which diabetic fatty liver accounts for a large proportion, with 50 to 75% of the subjects demonstrating fat in the liver on ultrasound. As a result of epidemic increase in diabetes mellitus, hypertension, obesity and hyperlipidemia, the prevalence of NAFLD is increasing worldwide.

Methods: A study was conducted on a total 100 type-2 diabetes mellitus patients attending Geetanjali Medical College and Hospital, Udaipur, Rajasthan. Patients with known chronic liver disease and history of alcohol intake were excluded. These patients were evaluated by abdominal ultrasonography to determine the presence of fatty liver. They were divided into fatty liver group and non-fatty liver group; and were further evaluated by measurement of body mass index, Central obesity, HbA1c and lipid profile. The data obtained was analyzed using SPSS version 20.0.

Results: Of the 100 diabetic patients enrolled in this study, 64 (64%) presented with NAFLD. The highest prevalence of NAFLD was recorded in the age group of 50-59 years at 37.5%. The prevalence rate among males (65.62%) was higher than for females (34.38%). A comprised NAFLD patients (64%) and Non-NAFLD patients (34%).

Conclusions: This study revealed that the NAFLD is a vital part of cluster of abnormalities such as dysglycemia, dyslipidemia, hypertension and obesity. Age and duration of diabetes are also important contributing factors in occurrence of NAFLD.

References

Farrell GC, Larter CZ. Nonalcoholic Fatty Liver Disease: from Steatosis to cirrhosis. Hepatology. 2006;43:S00-S112.

Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New Eng J Med. 2010;363(14):1341-50.

Younossi ZM, Granlich T, Matteoni CA, Boparai N, McCullough AJ. Non-alcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2(3):262- 5.

Day CP. Non-alcoholic liver disease: Current concepts and management strategies. Clinical Med. 2006;6(1):19-25.

Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician. 2006;73(11):1961-8.

Farrell GC, Larter CZ. Nonalcoholic Fatty Liver Disease: from Steatosis to cirrhosis. Hepatology. 2006;43:S00-S112.

Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians Ind. 2009;57(3):205-10.

Snehalatha C, Viswanathan V, Ramachandran A. Cutoff values for normal anthropometric variables in Asian Indian adults. Diabetes care. 2003;26(5):1380-4.

International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2005. Available at https://www.idf.org /search.html?searchword=The%20IDF%20consensus%20worldwide%20definition%20of%20the%20metabolic%20syndrome&searchphrase=all.

Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Ame Coll Cardiol. 2004;44(3):720-32.

National Institutes of Health. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. NIH Pub.1997.

Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterol. 2002;30;123(3):745-50.

Mishra S, Yadav D, Gupta M, Mishra H, Sharma P. Hyperinsulinemia predisposes to NAFLD. Ind J Clin Biochem. 2008;23(2):130-5.

Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, et al. Non‐alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;19(8):854-8.

Banerjee S, Ghosh US, Dutta S. Clinico-pathological profile of hepatic involvement in type-2 diabetes mellitus and its significance. JAPI. 2008;56(5):581-6.

Kalra S, Vithalani, M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India. 2013;61(7):448-53

Luxmi S, Sattar RA, Ara J. Association of non-alcoholic fatty liver with type 2 diabetes mellitus. JLUMHS. 2008;9:188-93.

Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a populationbased cohort study. Gastroenterol. 2005;129(1):113-21.

Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, et al. Predictors of Nonalcoholic Steatohepatitis (NASH) in Obese Patients Undergoing Gastric Bypass. Obesity Surgery. 2005;15(8):1148-53.

Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obesity Surgery. 2005;15(8):310-5.

Angulo P. Nonalcoholic fatty liver disease. New Eng J Med. 2002;346(16):1221-31.

Downloads

Published

2018-03-28

How to Cite

Patel, H., & Verma, Y. N. (2018). Prevalence of non-alcoholic fatty liver disease in type-2 diabetes mellitus patients. International Journal of Research in Medical Sciences, 6(4), 1322–1326. https://doi.org/10.18203/2320-6012.ijrms20181290

Issue

Section

Original Research Articles